Welcome to our dedicated page for Harrow Health news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow Health stock.
Harrow, Inc. (Nasdaq: HROW) is an ophthalmic-focused pharmaceutical company that regularly issues news and updates related to its portfolio of eye-care products, development programs, and corporate activities. The company describes itself as a leading provider of ophthalmic disease management solutions in North America, with products that address conditions such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma, ocular surface conditions, and retina diseases.
News about Harrow commonly covers financial results and investor communications, including quarterly earnings releases, letters to stockholders, and conference call announcements. The company also announces participation in investor conferences and Investor & Analyst Day events, where it provides overviews of its commercial portfolio, pipeline, and long-term vision.
Another key theme in Harrow’s news flow is business development and pipeline progress. Recent press releases have described the agreement to acquire, and subsequent closing of the acquisition of, Melt Pharmaceuticals, Inc., a clinical-stage company developing non-opioid, non-IV sedation therapies such as MELT-300 and MELT-210. Harrow has used these announcements to explain the strategic rationale for expanding into procedural sedation and to outline regulatory and development milestones for these product candidates.
Harrow’s news also highlights access and affordability initiatives, such as the launch of the VEVYE Access for All (VAFA) program for VEVYE (cyclosporine ophthalmic solution) 0.1% and the broader Harrow Access for All (HAFA) program, which is intended to extend a unified access model across its branded, authorized generics, and compounded ophthalmic medications. Additional releases address leadership changes at ImprimisRx, debt offerings and related credit facilities, and other corporate matters.
Investors and eyecare professionals reviewing Harrow’s news page can expect updates on earnings, capital markets transactions, acquisitions, development milestones for ophthalmic and procedural sedation candidates, and initiatives aimed at improving patient access to the company’s ophthalmic therapies.
NASHVILLE, Tenn. -- Harrow Health (NASDAQ: HROW) announced participation in the virtual H.C. Wainwright BioConnect Conference from January 10-13, 2022. CEO Mark L. Baum and CFO Andrew Boll will represent the company. A pre-recorded presentation will be available on Harrow's investor relations website starting January 10 at 7:00 a.m. ET, remaining accessible for 90 days. Harrow Health specializes in ophthalmic healthcare and operates ImprimisRx and Visionology, focusing on innovative eye care solutions.
Melt Pharmaceuticals announced the filing of two INDs with the FDA for non-opioid formulations MELT-210 and MELT-400. The company is actively dosing patients for its Phase 2 pivotal efficacy study of MELT-300, which is expected to complete enrollment by early Q2 2022. MELT-300 offers a needle-free, opioid-free alternative for sedation during cataract surgeries, potentially eliminating the need for opioids and contributing to addressing the opioid crisis. Top-line results are anticipated by the end of Q2 2022.
Harrow Health (NASDAQ: HROW) announced the acquisition of U.S. commercialization rights for four FDA-approved ophthalmic medications from Novartis for $14 million. The products include IOPIDINE®, MAXITROL®, and MOXEZA®, which will enhance Harrow's portfolio in the ophthalmic surgical and acute care markets. This acquisition positions Harrow as a unique provider of both branded products and compounded formulations in the U.S. market, leveraging its ImprimisRx platform for distribution.
Harrow Health, Inc. (Nasdaq: HROW) has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective December 20, 2021. This inclusion is a recognition of the company's performance among biotechnology and pharmaceutical securities. CEO Mark L. Baum expressed pride in this milestone, viewing it as validation of the team's efforts to create value for stakeholders. Harrow Health focuses on ophthalmic healthcare, operating ImprimisRx and Visionology, and has interests in other pharmaceuticals. The company aims to provide innovative and affordable eye care solutions.
Harrow Health reports record revenues of $18.7 million for Q3 2021, marking a 30% increase from $14.4 million in the same period last year. The company maintains a gross margin of 74% and achieved commissions from DEXYCU® sales of $900,000. Harrow acquired two FDA drug candidates, AMP-100 and MAQ-100, aiming to enhance its product offerings. Cash and cash equivalents stood at $57.9 million as of September 30, 2021. CEO Mark L. Baum emphasized strong revenue growth, despite challenges posed by COVID-19.
Harrow Health, Inc. (NASDAQ: HROW) will release its third-quarter financial results for 2021 on
Harrow Health, Inc. (NASDAQ: HROW) announced a $13.5 million senior secured loan to Melt Pharmaceuticals, Inc. to support the Phase 2 study of its lead drug candidate MELT-300, aimed at providing a non-opioid solution for sedation during cataract surgery. Melt plans to dose the first patient in
Summary not available.
Harrow Health (NASDAQ: HROW), an ophthalmic-focused healthcare company, announced that Mark L. Baum, CEO, and Andrew Boll, CFO, will participate in two virtual investor conferences. The first is the H.C. Wainwright Ophthalmology Virtual Conference on August 17, 2021, where a pre-recorded presentation will be available on their website from 7:00 a.m. ET. The second is the Lake Street Capital Market’s 5th Annual Best Ideas Growth Conference on September 15, 2021, where management will hold one-on-one meetings with investors.
Harrow Health, Inc. (NASDAQ: HROW) reported record financial results for Q2 and H1 ended June 30, 2021, marking its best quarter ever with significant growth in revenues, cash flow from operations, and Adjusted EBITDA. The company raised $75 million in unsecured capital, which is being utilized for strategic initiatives, including the acquisition of AMP-100, an ophthalmic anesthetic drug candidate, with an FDA application expected soon. Harrow anticipates a strong second half of 2021, aimed at enhancing product diversity and operational performance.